AN2 Therapeutics, Inc. (ANTX)
$4.30-2.27%Close
SELLCRISIS · day 4
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $155M
- Beta
- -0.98
- P/E (TTM)
- -3.36
- Short % float
- 12.47%
- Days to cover
- 9.5
- SI change
- +4.0%
- 1W
- -23.35%
- 1M
- -20.52%
- vs SPY 1W
- -23.77%
- vs SPY 1M
- -22.58%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on ANTX?
- LOPJLB’s latest quantitative signal on AN2 Therapeutics, Inc. (ANTX) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is ANTX in?
- AN2 Therapeutics, Inc. (ANTX) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does AN2 Therapeutics, Inc. (ANTX) do?
- AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease.…